ZB716, a fulvestrant-3 boronic acid derivative, is primarily explored in the field of cancer research, particularly for targeting estrogen receptor-positive (ER+) breast cancer. It functions as a selective estrogen receptor degrader (SERD), effectively binding to estrogen receptors and promoting their degradation, thereby inhibiting estrogen-dependent cancer cell growth. This compound is being investigated for its potential to overcome resistance to traditional endocrine therapies, offering a promising approach for patients with advanced or metastatic breast cancer. Additionally, its boronic acid moiety may enhance binding affinity and pharmacokinetic properties, making it a candidate for further development in targeted cancer therapies. Research is ongoing to evaluate its efficacy, safety, and potential clinical applications.